Levothyroxine Dose Adjustment for TSH 18.5 mIU/L

Increase the levothyroxine dose by 25 µg (from 88 µg to 112 µg or 113 µg daily) and recheck TSH in 4–8 weeks. 1

Rationale for Dose Increase

A TSH of 18.5 mIU/L is markedly elevated and signals severe undertreatment despite the current 88 µg dose. 1
When baseline TSH exceeds 10–12 mIU/L, a 25 µg increment (rather than the standard 12.5 µg) is appropriate to achieve faster normalization. 1, 2
The target TSH range for primary hypothyroidism is 0.3–4.1 mIU/L (preferably the lower half of this range for optimal symptom relief). 1, 3

Non-compliance is the most common cause of persistently elevated TSH in patients on levothyroxine, especially at doses >100 µg/day. 1, 2
Directly ask the patient about missed doses and confirm they are taking the medication consistently every day. 1
Verify proper administration: levothyroxine must be taken on an empty stomach, 30–60 minutes before breakfast with water, or at bedtime ≥4 hours after the last meal. 1, 2, 3
Ensure the patient is not taking levothyroxine within 4 hours of calcium, iron, proton-pump inhibitors, antacids, or bile-acid sequestrants, as these markedly reduce absorption. 1, 2, 3
Meals, coffee, soy products, walnuts, and high dietary fiber also diminish absorption and should be avoided around the time of ingestion. 2

Increase to 112 µg or 113 µg daily (a 25 µg increment from 88 µg). 1, 2
Recheck TSH in 4–8 weeks to allow the new steady-state hormone level to be reached. 1, 2, 4
If TSH remains elevated at the 4–8 week check, add another 12.5–25 µg increment and repeat TSH testing after another 4–8 weeks. 1, 2
Continue this titration cycle until TSH falls within the target range of 0.3–4.1 mIU/L. 1, 3
Once TSH is stable within the target range, schedule follow-up TSH assessments every 6 months initially, then annually. 1, 2

Patients ≥50–60 years without known coronary disease: A 25 µg increase from 88 µg to 112 µg is safe and appropriate. 1, 2
Patients with known coronary heart disease: Use smaller dose increments (12.5 µg) and monitor for anginal symptoms after each change to avoid precipitating myocardial ischemia. 1, 2, 3
Elderly patients (≥65 years): Generally require 20–25% less levothyroxine per kilogram of body weight because of reduced lean body mass, but a TSH of 18.5 mIU/L still warrants a 25 µg increase. 1, 2
Use smaller increments (12.5 µg) in the elderly to avoid overtreatment and atrial fibrillation once TSH approaches the target range. 1, 2

Do not ignore an elevated TSH simply because free T4 is normal (if measured); this pattern still denotes undertreatment that warrants dose increase. 1
Do not assume malabsorption before confirming perfect compliance and proper administration; non-compliance is far more prevalent. 1, 2
Do not increase levothyroxine beyond 200 µg/day without first thoroughly investigating compliance and absorption issues. 1, 2
Do not rely on free T4 or T3 levels alone as therapeutic endpoints; TSH remains the most reliable marker for primary hypothyroidism. 1, 2

Once TSH normalizes, avoid overtreatment: a suppressed TSH (<0.1 mIU/L) is linked to increased cardiovascular risk (especially atrial fibrillation in the elderly) and accelerated bone loss in postmenopausal women. 1, 2, 3
Approximately 20% of patients on levothyroxine become overtreated, which substantially raises the risk of adverse cardiovascular and skeletal events. 1, 2, 3

Before escalating levothyroxine in patients at risk for adrenal insufficiency (e.g., central hypothyroidism, pituitary disease), administer physiologic hydrocortisone until adrenal insufficiency is ruled out to avoid precipitating adrenal crisis. 1, 2
In primary hypothyroidism (the most common scenario), adrenal insufficiency is rare and this step is not routinely necessary. 1